Short Interest in Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Rises By 254.8%

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 51,800 shares, a growth of 254.8% from the February 28th total of 14,600 shares. Based on an average daily volume of 85,100 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.0% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. KGaA in a report on Monday, February 3rd.

Fresenius SE & Co. KGaA Stock Performance

OTCMKTS FSNUY traded up $0.01 on Thursday, reaching $10.87. 41,135 shares of the company’s stock traded hands, compared to its average volume of 54,716. Fresenius SE & Co. KGaA has a fifty-two week low of $6.57 and a fifty-two week high of $11.23. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.05 and a current ratio of 1.36. The firm has a market cap of $24.28 billion, a price-to-earnings ratio of 51.75 and a beta of 1.02. The stock has a 50 day moving average price of $10.10 and a 200-day moving average price of $9.43.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.18 earnings per share (EPS) for the quarter. The company had revenue of $6.01 billion during the quarter. Equities research analysts predict that Fresenius SE & Co. KGaA will post 0.79 EPS for the current fiscal year.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.